roxithromycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	2410	80214-83-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: roxithromycin rotramin claramid roxacin roxeptin Roxithromycin A	Semisynthetic derivative of erythromycin. It is concentrated by human phagocytes and is bioactive intracellularly. While the drug is active against a wide spectrum of pathogens, it is particularly effective in the treatment of respiratory and genital tract infections. Molecular weight: 837.06 Formula: C41H76N2O15 CLOGP: 2.20 LIPINSKI: 2 HAC: 17 HDO: 5 TPSA: 216.89 ALOGS: -3.65 ROTB: 13

Molecule

Description

Molfile Inchi Smiles

Synonyms:

roxithromycin
rotramin
claramid
roxacin
roxeptin
Roxithromycin A

Semisynthetic derivative of erythromycin. It is concentrated by human phagocytes and is bioactive intracellularly. While the drug is active against a wide spectrum of pathogens, it is particularly effective in the treatment of respiratory and genital tract infections.

Molecular weight: 837.06
Formula: C41H76N2O15
CLOGP: 2.20
LIPINSKI: 2
HAC: 17
HDO: 5
TPSA: 216.89
ALOGS: -3.65
ROTB: 13

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.19 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	12 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1987	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Jaundice	38.35	30.12	18	1221	53331	79689818

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01FA06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Macrolides
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.96	acidic
pKa2	8.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Motilin receptor	GPCR	O43193	MTLR_HUMAN	AGONIST	IC50	6.20	IUPHAR
50S ribosomal protein L10	Ribosomal protein		RL10_HALMA				WOMBAT-PK
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	6.26	DRUG MATRIX

External reference:

ID	Source
N0000168422	NUI
D01710	KEGG_DRUG
C0035891	UMLSCUI
CHEBI:48935	CHEBI
ROX	PDB_CHEM_ID
CHEMBL1214185	ChEMBL_ID
D015575	MESH_DESCRIPTOR_UI
DB00778	DRUGBANK_ID
1465	IUPHAR_LIGAND_ID
5815	INN_ID
21KOF230FA	UNII
6915744	PUBCHEM_CID
9478	RXNORM
004199	NDDF
713769006	SNOMEDCT_US
96037004	SNOMEDCT_US

Pharmaceutical products:

None